Atlas Trials

Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer

Clinical trial NCT04238624 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04238624
Sponsor
Memorial Sloan Kettering Cancer Center
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Anaplastic Thyroid CancerThyroid CancerBRAF Gene MutationBRAF Mutation-Related Tumors
Start date
2020-01-20
Primary completion
2027-06-20
Enrollment
16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.